Unlock instant, AI-driven research and patent intelligence for your innovation.

Two kinds of novel angiogenesis-inhibiting medicine and its uses in preventing and treating tumour

An angiogenesis inhibitory, drug-based technology, applied in the field of molecular pharmacology

Inactive Publication Date: 2008-11-12
刁勇 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a concern is that in clinical trials, whether the effective drug concentration has been reached in the tumor, and whether the concentration can be maintained for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Two kinds of novel angiogenesis-inhibiting medicine and its uses in preventing and treating tumour
  • Two kinds of novel angiogenesis-inhibiting medicine and its uses in preventing and treating tumour
  • Two kinds of novel angiogenesis-inhibiting medicine and its uses in preventing and treating tumour

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] (1) Construction of rAAV-kallistatin and rAAV-vasostatin

[0029] The cDNAs of kallistatin and vasostatin were obtained by PCR, and the correctness was verified by DNA sequencing. The sequence of Kallistatin is identical to that reported by NCBI except for two nucleotides. Its two different nucleotides are listed at positions 1145 and 1146, resulting in a mutation, the original threonine becomes serine ( figure 1 A). Because vasostatin is a fragment of calreticulin, after the 180th codon of calreticulin, a stop codon (TAG) is introduced through the 3' primer, and truncated calreticulin, namely vasostatin, is generated after translation. The sequence of vasostatin is identical to the nucleotides 54-594 of calreticulin reported by NCBI.

[0030] In order to obtain constitutive high expression of kallistatin and vasostatin, the two cDNAs were respectively inserted between the ITRs of the AAV vector, and the promoters were CMV enhancer / chicken β-actin promoter. To enhan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to two kinds of angiogenesis inhibiting medicines based on kallistatin and vasostatin separately. The medicines are constituted by means of gene engineering technology, and can express recombinant adeno-associated virus of kallistatin and / or vasostatin. The medicines are used in treating tumor, preventing tumor recurrence and metastasis, and raising the curative effect of chemotherapy and radiotherapy of tumor.

Description

technical field [0001] The present invention relates to molecular pharmacy, biotechnology and disease prevention and treatment, in particular to two angiogenesis inhibitory drugs based on kallistatin and vasostatin, and using the drug to treat tumors, or prevent tumor recurrence or metastasis, and enhance tumor chemotherapy or The application of radiation therapy. Background technique [0002] At present, malignant tumors have become the leading fatal diseases in developed countries and regions. Although surgery, radiotherapy and chemotherapy are still being developed as conventional treatments, due to their inherent limitations, their curative effect has basically reached the limit, so there is an urgent need to develop new treatments. [0003] Liver cancer ranks sixth among the most common cancers in the world. Among various types of liver cancer, hepatocellular carcinoma (HCC) is the most common primary malignant liver cancer. The International Agency for Research on C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61K38/16A61K9/08A61K9/14A61P35/00
Inventor 许瑞安谢礼贤刁勇
Owner 刁勇